Replimune's skin cancer drug is rejected again by the US FDA, causing the company's stock price to plummet
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Replimune expressed opposition to the FDA’s decision, with the company’s Chief Executive Officer (CEO) stating that, given the robust efficacy and favorable safety data supporting the drug, the FDA failed to exercise regulatory flexibility to meet patient needs.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
BCH Surpasses $280
Cointime•2026/09/22 12:37
Fiserv’s Clover partners with Winnipeg Blue Bombers to run venue commerce operations
Bitget•2026/09/22 12:33
XFLH Capital signs LOI for business combination with Renogen Biolab
Bitget•2026/09/22 12:33
Crypto prices
More
Bitcoin
BTC
$86,140.09
+1.28%
Ethereum
ETH
$2,749.84
+1.06%
Tether USDt
USDT
$0.9999
+0.03%
BNB
BNB
$786.28
-0.31%
XRP
XRP
$1.54
+3.53%
USDC
USDC
$1.0000
+0.03%
Solana
SOL
$117.42
+0.89%
TRON
TRX
$0.3458
+0.46%
Zcash
ZEC
$1,532.51
-0.40%
Hyperliquid
HYPE
$95.87
+0.56%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now